Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.
CPT codes and LOINC update: March 2023 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of March.
Research Archives - Page 25 of 33 - Insights
Skip to Content MayoACCESS MayoLINK...
Research Roundup Archives - Page 21 of 29 - Insights
Skip to Content MayoACCESS MayoLINK...
https://news.mayocliniclabs.com/file-autoimmune-neurology-test-ordering-guide/
N EURO LO GY START ORDERING TODAY. PUT YOUR PATIENTS ON THE PATH TO THE RIGHT ANSWER. CALL 800-533-1710 OR VISIT MAYOCLINICLABS.COM/CUSTOMER-SERVICE/CONTACTS. N EURO LO GY © 2024 Mayo Foundation for Medical Education and Research. All...
Mayo Clinic Laboratory and Pathology Research Roundup: April 10 - Insights
This week’s Research Roundup highlights thyroid hormone treatment among pregnant women with subclinical hypothyroidism.
Mayo Clinic Laboratory and Pathology Research Roundup: December 12 - Insights
This week's research roundup feature: Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic...